New diagnostic technology accurately tests for anemia and sickle cell disease
Researchers from Case Western Reserve University today presented research in which Hemex Health’s Gazelle platform diagnostic technology successfully tested 46 patients with a sensitivity of 100% and a specificity of over 92. , 3% for anemia and with 100% accuracy for hemoglobin variants.
The preliminary study included blood samples taken from patients in the Cleveland area studied for anemia and sickle cell disease.
The single combined test for anemia and sickle cell anemia is considered a first and is expected to provide an essential new tool for disease detection and management in low-resource settings where incidents of sickle cell disease are numerous and often undiagnosed. This test should be available mid-2021 after regulatory approval in the identified countries.
Health professionals we spoke with in Africa and Asia told us that one of the biggest barriers to better diagnosis and management of anemia and sickle cell anemia is the lack of a affordable and easy-to-use test that can provide regular data to help optimize treatment. Case Western Reserve study demonstrates that a software enhancement to our Gazelle platform has the potential to enable our current sickle cell test to also check for anemia, which could help clinicians and patients optimize management disease through a single low-cost test.. “
Patti White, Study Co-Founder and CEO, Hemex Health
The research team compared the study samples to the current standard clinical detection of anemia (complete blood count [CBC]) and sickle cell anemia (High Performance Liquid Chromatography [HPLC]).
“With an integrated total hemoglobin and variant hemoglobin test, clinicians can help patients better understand their condition, as iron deficiency and nutrition issues can cause anemia without a patient suffering from sickle cell disease. Said Umut Gurkan, PhD, Associate Professor, Case Western Reserve University, principal investigator of the team that presented the results at the 62nd Annual Meeting of the American Society of Hematology. “Gazelle reminds me of Tesla because technology transforms with a software upgrade, and that’s all it takes to add hemoglobin testing to the existing platform.”